Steve Kemler

Jan 4, 2024 | outsourcedpharma.com | Peter Alexander |Phillip Ramsey |Peter H. Calcott |Steve Kemler |Louis Garguilo

Get more pharma outsourcing insight with our FREE newsletter Newsletter | January 4, 2024 BEST OF INDUSTRY INSIGHTSConnect With Outsourced Pharma:

Mar 27, 2023 | outsourcedpharma.com | Steve Kemler |Danica Brown |Theo Zacharatos |Laurel Ferenchick |Louis Garguilo

Article | By Laurel Ferenchick, PCI Pharma Services, and Marc Lisi, Suvoda Experts speak on supply capabilities within interactive response technology (IRT) — how flexibility is important to functionality, who to involve, and which questions to ask in optimizing IRT for clinical supply.

Feb 23, 2023 | biosimilardevelopment.com | Steve Kemler

By Steve Kemler, life sciences senior analyst, RSM US LLP Last year was a transition year for biotech companies. After massive investment, cheap capital, and public accolades for companies developing Covid treatments and vaccines during the pandemic, 2022 saw the initial public offering market grind to a halt and a slowing of new drug approvals. Now, as the biotech sector prepares plans for the remainder of this year, companies are faced with continued uncertainty.

Feb 23, 2023 | lifescienceleader.com | Steve Kemler

By Steve Kemler, life sciences senior analyst, RSM US LLP Last year was a transition year for biotech companies. After massive investment, cheap capital, and public accolades for companies developing Covid treatments and vaccines during the pandemic, 2022 saw the initial public offering market grind to a halt and a slowing of new drug approvals. Now, as the biotech sector prepares plans for the remainder of this year, companies are faced with continued uncertainty.

Feb 23, 2023 | bioprocessonline.com | Steve Kemler

By Steve Kemler, life sciences senior analyst, RSM US LLP Last year was a transition year for biotech companies. After massive investment, cheap capital, and public accolades for companies developing Covid treatments and vaccines during the pandemic, 2022 saw the initial public offering market grind to a halt and a slowing of new drug approvals. Now, as the biotech sector prepares plans for the remainder of this year, companies are faced with continued uncertainty.